Proteinase K Market Size, Share and Global Trend By Type (Recombinant, Naturally extracted), By Form (Lyophilised powder, Solution), By Application (Next generation sequencing, Microarray techniques, Mitochondria isolation, Endotoxin removal, Others), By End User (Bio-Pharmaceutical companies, Pharmaceutical companies, Research Institutes), and Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
In February 2019, Promega Corporation launched Maxwell RSC miRNA Plasma and Serum Kit for miRNA purification. Proteinase K is an extremely active serine protease enzyme that has extensive cleavage specificity on denatured and native proteins. Proteinase K also cleaves a wide range of peptide bonds and is predominantly utilized to perform enzymatic reactions or cell lysates. Proteinase K is widely used in research studies carried out in industries and research institution. The rise in the demand of next generation sequencing in gene therapy combined with the introduction of novel technologies like CRISPR/Cas9 is anticipated to fuel the market of global proteinase k market.
The global proteinase K market is expected to grow rapidly during the forecast period, owing to high research and development activities and investment by research institutes, biopharmaceutical and others in the development of proteinase K. Additionally, increasing usage of proteinase K in different applications such as nucleic acid and mitochondrial isolation, growing use of proteinase K in drug discovery, disease diagnosis, and introduction of new proteinase K by different market players are some of the factors drive the growth of the global proteinase K market in the forecast period.
To gain extensive insights into the market, Request for Customization
However, purity of the available proteinase K in the market and presence of other proteins and nucleases in the proteinase K are some of the major factors restraining the growth of the global proteinase K market.
Key Players Covered
Some of the major companies that are present in the global proteinase K market are Thermo Fisher Scientific Inc., Merck KGaA, Qiagen N.V., Worthington Biochemical Corporation, Sisco Research Laboratories Pvt. Ltd, Promega Corporation, Bioline, F. Hoffmann-La Roche AG and others.
SEGMENTATION
SEGMENTATION | DETAILS |
By Type | · Recombinant · Naturally extracted |
By Form | · Lyophilised powder · Solution |
By Application | · Next generation sequencing · Microarray techniques · Mitochondria isolation · Endotoxin removal · Others |
By End User | · Bio-Pharmaceutical companies · Pharmaceutical companies · Research Institutes · Others |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
Among the form of proteinase K, lyophilized powder is anticipated to register the highest share in the global proteinase K market owing to the longer shelf life of the product.
Key Insights
- Pricing analysis
- Regulatory scenario for key countries
- Key Industry Developments - Mergers, Acquisitions and Partnerships, 2018
- Porter’s five forces analysis
Regional Analysis
The global proteinase K market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to lead the global proteinase market in 2018 followed by Europe, owing to increase in investment in research and development by government organizations, rise in demand of the proteinase in K owing to increase in demand of gene therapy and rising adoption of low cost of the proteinase K product in the region. The Asia Pacific region is expected to register comparative higher CAGR from 2019 - 2026 due to the rise in genetic disorders leading to increase in demand of novel diagnosis and treatments, growing emphasis by healthcare organization and evolving healthcare infrastructure.
Key Industry Developments
- In May 2019, Thermo Fisher Scientific Inc. has announced the company’s investment in expansion of global bio production capabilities.
- In May 2018, Worthington Biochemical Corporation completed companywide ISO recertification after auditing by ANAB-accredited SGS US Testing Company, Systems & Services Certification.
- Ongoing
- 2023
- 2019-2022
-
Get in Touch with Us
-
US +1 833 909 2966 ( Toll Free )
-
